DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • France
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
VIRP logo

Virbac SA Stock Price

ENXTPA:VIRP Community·€2.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

VIRP Share Price Performance

€0
-325.00 (-100.00%)
​
€412.88
Fair Value
€0
-325.00 (-100.00%)
​
Price €0
Sun, 7 Jun 26
Fair Value€412.88
Share Pricen/a

VIRP Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €412.88 26.9% undervalued intrinsic discount

Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
VIRP logo
Virbac
26.9% undervalued intrinsic discount

Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 7 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
VIRP logo

VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing

Fair Value: €412.88 26.9% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with excellent balance sheet.

0 Risks
5 Rewards
View Full Analysis

Virbac SA Key Details

€1.5b

Revenue

€488.0m

Cost of Revenue

€976.7m

Gross Profit

€825.8m

Other Expenses

€150.9m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 17, 2026
18.01
66.68%
10.30%
22.3%
View Full Analysis

About VIRP

Founded
1968
Employees
6442
CEO
Paul Martingell
WebsiteView website
corporate.virbac.com

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Recent VIRP News & Updates

User avatar
Narrative Update • Jun 07

VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing

Analysts have maintained their price target for Virbac at €412.88, citing unchanged assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Virbac has scheduled a Special and Extraordinary Shareholders Meeting for June 29, 2026.

Recent updates

No updates

Virbac SA Competitors

IPN logo

Ipsen

Symbol: ENXTPA:IPN
Market cap: €12.8b
ERF logo

Eurofins Scientific

Symbol: ENXTPA:ERF
Market cap: €12.3b
ABVX logo

ABIVAX Société Anonyme

Symbol: ENXTPA:ABVX
Market cap: €8.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide